MassDevice.com Q&A: Medtronic CEO Omar Ishrak (MassDevice)
Medtronic CEO Omar Ishrak tells MassDevice.com about how he screens potential acquisitions, his plan to re-shape the company and handling the controversy over the Infuse spine treatment.
Just a few days into his tenure as CEO of Medtronic (NYSE:MDT), Omar Ishrak was confronted with a major crisis: The Spine Journal devoted its entire June issue to to exposing problems with growth proteins, including a repudiation of some of the research surrounding Infuse.
The ensuing clamor, which included federal investigations ...
The Orthopedics Industry 
